Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study

INTRODUCTION: Glecaprevir/pibrentasvir (G/P) has demonstrated high rates (>95%) of sustained virologic response at posttreatment Week 12 (SVR12) in treatment-naïve (TN) patients with hepatitis C virus (HCV) infection and compensated cirrhosis (CC). Here, in a key real-world subset of TN Italian p...

Descripción completa

Detalles Bibliográficos
Autores principales: Aghemo, Alessio, Persico, Marcello, D’Ambrosio, Roberta, Andreoni, Massimo, Villa, Erica, Bhagat, Abhi, Gallinaro, Valentina, Gualberti, Giuliana, Merolla, Rocco Cosimo Damiano, Gasbarrini, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894491/
https://www.ncbi.nlm.nih.gov/pubmed/36730135
http://dx.doi.org/10.1371/journal.pone.0280165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894491/
https://www.ncbi.nlm.nih.gov/pubmed/36730135
http://dx.doi.org/10.1371/journal.pone.0280165

Ejemplares similares